Veliparib (ABT-888)

For research use only.

Catalog No.S1004 Synonyms: NSC 737664

163 publications

Veliparib (ABT-888) Chemical Structure

CAS No. 912444-00-9

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 227 In stock
USD 370 In stock
USD 617 In stock
USD 990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Veliparib (ABT-888) has been cited by 163 publications

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 M3zm[WtqdmG|ZTDBd5NigQ>? NEe5Uo4{OCCvaX6= MYLJcohq[mm2aX;uJI9nKFCDUmCxJJdqfGhiRVO1NEBw\iByLkCwNkDPxE1? Mn3LNVk5QDh5NkC=
Jurkat NX\We2g5U2mwYYPlJGF{e2G7 MkjuPVYhcA>? Mkj4SG1UVw>? MX;Jcohq[mm2aX;uJI9nKFCDUmCxJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSC5aYToJGVEPTBib3[gN{DPxE1? Mn7oNlM5PTBzOUm=
Capan1 NYHDXXZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDEZVVvPzJiaB?= NV[2SIFFTE2VTx?= MmPURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? MVKyOFM6QDN6Mx?=
DT40 MVTDfZRwfG:6aXOgRZN{[Xl? NIHTfY04OiCq Mn;FSG1UVw>? MmXmR5l1d3SxeHnjbZR6KGGpYXnud5Qh[2irY3vlckBDWkODMj3k[YZq[2mnboSgSHQ1OCClZXzsdy=> MY[yOFkzOjV6Nx?=
ML-1 MWrBdI9xfG:2aXOgRZN{[Xl? NITvbWIzNjVizszN Ml7QNlQhcA>? NV;CRpR5TE2VTx?= M1z1bnN6dmW{Z3nzeIlk[WyueTDlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDNUE0yKGOnbHzz NFfsUYIzPDh7NUGzOS=>
HCT-116 MXXLbY5ie2ViQYPzZZk> NF7NXpcxNjVizszN M1HvRlI1KGh? NV;0Z2txWEGUUDDhZ5Rqfmm2eTDk[YNz\WG|ZYO= MUKyN|A2PDJzMx?=
UM-SCC1 NWLveVJbS3m2b4TvfIlkKEG|c3H5 MnH0NVAh|ryP NFzLe4MzPCCq NYeyU5FpWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> NGD4WVQzOTlzMk[yNC=>
FaDu NHPCU5lEgXSxdH;4bYMhSXO|YYm= MX:xNEDPxE1? NH;4fFgzPCCq NEDQRWtT\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> NHfGenEzOTlzMk[yNC=>
PC-3 Mlu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjUNVAh|ryP NWPlWoNvUW6mdXPld{BiKHOrZ37p[olk[W62IHnubIljcXSrb36gbY4h[2:ub375JIZwem2jdHnvcuKh MlT3NlE2PzF7MUK=
EoL-1-cell MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HSWWlEPTB;MT6wO|k5KM7:TR?= M{LzRXNCVkeHUh?=
NCI-SNU-5 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPVTWM2OD1|LkGyPFQyKM7:TR?= M2nob3NCVkeHUh?=
BV-173 MojUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfUSIM{UUN3ME21MlQ2PDB7IN88US=> M3T3VHNCVkeHUh?=
HCC1806 NUK3N5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTVwN{WxO|Mh|ryP MkLiV2FPT0WU
COLO-680 M2m3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\YZmlEPTB;Nj6yNVQxPiEQvF2= M2T2bnNCVkeHUh?=
HCC2218 M{nQN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf6[FNKSzVyPUeuO|k4ODRizszN NXPndVdzW0GQR1XS
SK-MEL-24 NHTWUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTdwOEG5NlQh|ryP NILjWFZUSU6JRWK=
NCI-H720 NHvnUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zWTWlEPTB;OD60N|YxOyEQvF2= MVXTRW5ITVJ?
KASUMI-1 M17TWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\0Wm5KSzVyPUiuPFkzPjZizszN MkPJV2FPT0WU
HAL-01 NGnrclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3K3PGlEPTB;OT64PFYzKM7:TR?= MU\TRW5ITVJ?
CAL-33 NWe4RYpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fy[2lEPTB;MUCuOFM1KM7:TR?= MUXTRW5ITVJ?
SK-MEL-1 NYLQZ2hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fEeGlEPTB;MUKuOFY3OyEQvF2= MUXTRW5ITVJ?
Ramos-2G6-4C10 M4m5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXZc|RZUUN3ME2xNk41PzV{IN88US=> Ml;LV2FPT0WU
KY821 NV;GU|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzXfllpUUN3ME2xNk41QDVizszN MVrTRW5ITVJ?
HEC-1 M2\iemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTF{LkmxPVYh|ryP MYfTRW5ITVJ?
SK-NEP-1 NIC2WnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTF|LkG2OkDPxE1? NXX5N|FWW0GQR1XS
MN-60 M4PLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF|LkWzPFkh|ryP M375dnNCVkeHUh?=
DU-145 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzQVY1KSzVyPUGzMlkxPTNizszN NEfWNXFUSU6JRWK=
EW-3 NGP6XIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{X6cmlEPTB;MUSuOVU3PSEQvF2= MlHkV2FPT0WU
OS-RC-2 NUfVd|U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fQVGlEPTB;MUWuPVU5QSEQvF2= M1mzWHNCVkeHUh?=
RPMI-8226 NEPJZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTwTWM2OD1zNj6yNFQzKM7:TR?= MXLTRW5ITVJ?
ChaGo-K-1 MkDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M320PWlEPTB;MU[uOVMzPSEQvF2= NHPKU4FUSU6JRWK=
DEL MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;Zd4ZKSzVyPUG2MlY4OTdizszN NVq4NWRFW0GQR1XS
GP5d NIn4XWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\qVpVKSzVyPUG3MlA2OyEQvF2= MoGyV2FPT0WU
COLO-668 NV7jXGdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fUNWlEPTB;MUeuOlI6PCEQvF2= NFvKWHZUSU6JRWK=
H9 NELiXpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLCTWM2OD1zOD6yPFM{KM7:TR?= NYPOToJoW0GQR1XS
NKM-1 NYHmXWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULrOHFwUUN3ME2xPE42OTF7IN88US=> Ml;lV2FPT0WU
KYSE-150 M4K2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTF6Lkm5PFYh|ryP MVvTRW5ITVJ?
Daoy MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfSTWM2OD1zOT61OlQ6KM7:TR?= M3[0e3NCVkeHUh?=
ECC10 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJyLke0OVUh|ryP MoDiV2FPT0WU
A388 NF7DcmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzIcpFKSzVyPUKxMlkxQTFizszN MV7TRW5ITVJ?
MHH-NB-11 NWTNfpJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ|LkGzOlMh|ryP NWnjTVNuW0GQR1XS
HCC1937 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zpR2lEPTB;MkSuO|Q3KM7:TR?= M2fQPHNCVkeHUh?=
TGBC11TKB NI\hcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJ3Lk[4OlMh|ryP M1PESXNCVkeHUh?=
CTV-1 Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHruT4pKSzVyPUK1Mlg6PjlizszN MUDTRW5ITVJ?
NCI-H2029 Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInxT3FKSzVyPUK2MlQzOzhizszN NYHQTVBlW0GQR1XS
HLE MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrsdYxGUUN3ME2yO{4xPTRizszN MUfTRW5ITVJ?
NCI-H1693 M4PZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDYTWM2OD1{Nz6yPFk5KM7:TR?= MWLTRW5ITVJ?
HCC70 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL1TWM2OD1{Nz63NlQ3KM7:TR?= NF3iVGlUSU6JRWK=
BEN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T2cmlEPTB;MkeuPVU3PiEQvF2= NEjUPJBUSU6JRWK=
LB771 M2nLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDaTWM2OD1{OD64N|c{KM7:TR?= NE\xT4hUSU6JRWK=
697 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPUTWM2OD1{OT6wNlM2KM7:TR?= NYrEbWExW0GQR1XS
LU-139 Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4eySWlEPTB;MkmuN|c1QCEQvF2= MkDvV2FPT0WU
EW-13 M3PqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fjOGlEPTB;MkmuN|gyPCEQvF2= MnjUV2FPT0WU
MOLT-13 NVXBSY9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XIZ2lEPTB;MkmuN|gyPCEQvF2= M3\KeXNCVkeHUh?=
L-363 NXjqUHcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfuSZZtUUN3ME2yPU41Pzl6IN88US=> NEewOJVUSU6JRWK=
EM-2 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[3TWM2OD1{OT60PVAyKM7:TR?= MkHxV2FPT0WU
RS4-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm3TnJFUUN3ME2zNE41OjRzIN88US=> M{X2enNCVkeHUh?=
A2780 NHTzUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33DWWlEPTB;M{CuO|Q2PyEQvF2= NFL4UVFUSU6JRWK=
KU812 M3zUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN{LkO2OFIh|ryP NX;IUoNzW0GQR1XS
COLO-684 NYXPUW9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4riTmlEPTB;M{OuN|U6QSEQvF2= M3vTc3NCVkeHUh?=
MFE-280 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fj[2lEPTB;M{OuN|g5QSEQvF2= MonKV2FPT0WU
KG-1 MkHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTN|Lk[wNFEh|ryP M363PXNCVkeHUh?=
JVM-3 NXn3PIR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLKTWM2OD1|NT61PFY5KM7:TR?= NU\xSHNmW0GQR1XS
MV-4-11 M3\CTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;4RWlKSzVyPUO1Mlg1QTlizszN MorLV2FPT0WU
LAMA-84 NXyw[ZZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\Fb2lEPTB;M{[uO|M1PSEQvF2= MlXPV2FPT0WU
MOLT-16 M4T3cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHEWWNCUUN3ME2zOk46PTJizszN M1\LT3NCVkeHUh?=
H4 NEG5dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN5LkW2O{DPxE1? MYnTRW5ITVJ?
T47D NXHoXpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6RVR6UUN3ME2zO{44ODF6IN88US=> M{XZcnNCVkeHUh?=
CAL-54 MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PXVWlEPTB;M{euPVY3KM7:TR?= MmT4V2FPT0WU
SW982 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTN6LkC5PVgh|ryP M1vLfHNCVkeHUh?=
IGROV-1 NIe4cGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G1[mlEPTB;M{muN|MxPCEQvF2= MnW2V2FPT0WU
NB14 NF7IdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7MfYpHUUN3ME20NE44ODNzIN88US=> M3HVUXNCVkeHUh?=
HCC1187 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRzLkK3O|Eh|ryP NEmyb5FUSU6JRWK=
SBC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFiyN3NKSzVyPUSxMlMxPjNizszN NFvBNmNUSU6JRWK=
KARPAS-45 NFvVNVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XEZWlEPTB;NEGuOFgyQCEQvF2= NU\mNVhOW0GQR1XS
MOLT-4 NWCxeoxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;hWGlEPTB;NEKuNlU{QCEQvF2= M3nRW3NCVkeHUh?=
JVM-2 MkLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvKeVZTUUN3ME20Nk46OjB5IN88US=> M3vOWHNCVkeHUh?=
A4-Fuk M1ntfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PtcmlEPTB;NEOuOVY6OSEQvF2= NVXDeVFDW0GQR1XS
MDA-MB-361 NHLUPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojtTWM2OD12Mz64OFE1KM7:TR?= MYTTRW5ITVJ?
BALL-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTR|Lkm1N|Ih|ryP M33vbHNCVkeHUh?=
T98G MoizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj4dHNKSzVyPUS0Mlg2OTdizszN M3fPbXNCVkeHUh?=
Mo-T NYS2TYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T6bmlEPTB;NEWuOlM5QSEQvF2= NFPheFVUSU6JRWK=
MHH-PREB-1 NV[5SZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PlNmlEPTB;NEWuO|U5PSEQvF2= NH3vfGhUSU6JRWK=
ALL-PO NEXoRmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\WNGNKSzVyPUS3MlM4QTFizszN NIrRfY9USU6JRWK=
NCI-H510A MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[5TpNKSzVyPUS3MlkxOzRizszN NXH6Rpo6W0GQR1XS
ML-2 Mn2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jIVGlEPTB;NEmuO|g2PiEQvF2= MlTZV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

- Collapse
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664
Smiles CC1(CCCN1)C2=NC3=C(C=CC=C3N2)C(=O)N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Active not recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID